Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer |
Prostatic Neoplasms, Castration-Resistant | Phase1 | Australia South Africa |
NCT04597411 |
Study of Out of Specification for Tisagenlecleucel |
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | Phase3 | Japan | NCT04094311 |
Kesimpta Pregnancy and Infant Safety Study Using Real World Data |
Multiple Sclerosis | Switzerland | NCT06156683 | |
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent |
Multiple Sclerosis | United States | NCT04933552 | |
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN |
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis | Phase3 | Argentina Brazil China France Germany Greece Israel Italy Japan Netherlands Spain Switzerland Turkey (Türkiye) United Kingdom United States View all |
NCT03955445 |
Patient's Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation |
Hidradenitis Suppurativa | France | NCT06444087 | |
Regulatory Post-Marketing Surveillance Study for Brolucizumab |
Neovascular Age-related Macular Degeneration | South Korea | NCT04985487 | |
A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea |
Graft-versus-Host Disease | South Korea | NCT05621733 | |
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function |
Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase2 | France Germany Italy Spain United States View all |
NCT06004661 |
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria |
Uncomplicated Plasmodium Falciparum Malaria | Phase2 | Burkina Faso Côte d’Ivoire Gabon Ghana Kenya Uganda View all |
NCT05750628 |